Globe Newswire02.24.22
Balt has welcomed a new member to its legal department.
The company hired Jeffrey Sachs as chief Legal & Compliance officer. "I am thrilled to welcome Jeffrey to the Balt team. We are fortunate to have such a talented professional joining us in the Chief Legal & Compliance Officer role. As we continue to build our U.S.-based team, we are pleased to be adding further strength at the executive level," said Pascal Girin, president and CEO of Balt. "Jeffrey's extensive legal and compliance experience, along with a proven track record, will be a valuable addition to Balt."
Sachs joins Balt's C-Suite with more than 25 years of experience in relevant legal and compliance positions; he is based out of Balt's corporate office in Boston. Most recently, Sachs served as chief Legal and Compliance officer at Scipher Medicine, a venture-backed precision immunology company. Prior to that, he was vice president, senior associate general counsel at IQVIA, a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. Prior to his time with IQVIA, Sachs held various leadership positions within the legal organizations of several public and private companies and worked as an associate at Goodwin Procter LLP.
Sachs earned his J.D. from the University of Virginia School of Law and an A.B. from Brown University.
"I am very excited to join Balt and to contribute to a company making significant advancements in treating complex, life-threatening conditions," said Sachs. "I look forward to working with Pascal and the rest of the Balt organization, as the company continues to expand globally and bring its innovative product portfolio to the United States."
Since it was established in 1977, Balt has worked with interventional physicians to develop devices to treat complex life-threatening neurovascular conditions such as ischemic strokes, aneurysms, and arteriovenous malformations. A pioneer in the neurovascular field, Balt designs, manufactures, and distributes the broadest portfolio of products in the neurovascular space and is focused on expanding its geographic reach.
The company hired Jeffrey Sachs as chief Legal & Compliance officer. "I am thrilled to welcome Jeffrey to the Balt team. We are fortunate to have such a talented professional joining us in the Chief Legal & Compliance Officer role. As we continue to build our U.S.-based team, we are pleased to be adding further strength at the executive level," said Pascal Girin, president and CEO of Balt. "Jeffrey's extensive legal and compliance experience, along with a proven track record, will be a valuable addition to Balt."
Sachs joins Balt's C-Suite with more than 25 years of experience in relevant legal and compliance positions; he is based out of Balt's corporate office in Boston. Most recently, Sachs served as chief Legal and Compliance officer at Scipher Medicine, a venture-backed precision immunology company. Prior to that, he was vice president, senior associate general counsel at IQVIA, a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. Prior to his time with IQVIA, Sachs held various leadership positions within the legal organizations of several public and private companies and worked as an associate at Goodwin Procter LLP.
Sachs earned his J.D. from the University of Virginia School of Law and an A.B. from Brown University.
"I am very excited to join Balt and to contribute to a company making significant advancements in treating complex, life-threatening conditions," said Sachs. "I look forward to working with Pascal and the rest of the Balt organization, as the company continues to expand globally and bring its innovative product portfolio to the United States."
Since it was established in 1977, Balt has worked with interventional physicians to develop devices to treat complex life-threatening neurovascular conditions such as ischemic strokes, aneurysms, and arteriovenous malformations. A pioneer in the neurovascular field, Balt designs, manufactures, and distributes the broadest portfolio of products in the neurovascular space and is focused on expanding its geographic reach.